ecrin-mdr-crcClinical2024IPD Sharing (as of July 2023): NoMetastatic Colorectal CancerNeoplasm MetastasisMetastatic Gastric CancerMetastatic Breast CancerMetastatic Pancreatic CancerMetastatic Urothelial CarcinomaSolid tumorsMetastatic CancerMetastatic Colorectal CancerNeoplasm MetastasisMetastatic Gastric CancerMetastatic Breast CancerMetastatic Pancreatic CancerMetastatic Urothelial CarcinomaMetastatic CancerSolid TumorsInterventionalhttps://newmdr.ecrin.org/Study/661591CCR5ECRIN MDRNot yet recruitingfalseStudy of OB-002 in Patients With Refractory Metastatic CancerThis is an open-label, non-randomized trial with OB-002 monotherapy dose escalation followed by a dose expansion in patients with metastatic colorectal, pancreatic, gastric, breast, or urothelial cancer who have progressed on two or more treatment regimens.2024-01-1566159NCT05940844